Global Recombinant Coagulation Factor Concentrate Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Recombinant Coagulation Factor Concentrate market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Coagulation factor is the main drug for the treatment of hemophilia, and it has experienced the evolution and development from the first generation blood-derived coagulation factor products to the second generation recombinant products and the third generation long-acting recombinant products. Recombinant coagulation factors avoid the possibility of human infection and get rid of the dependence on plasma; long-acting products improve patient compliance and treatment convenience by prolonging the half-life of drugs, and long-acting recombinant coagulation factors are the trend of future research and development.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines. Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report is a detailed and comprehensive analysis for global Recombinant Coagulation Factor Concentrate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Recombinant Coagulation Factor Concentrate market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Coagulation Factor Concentrate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Coagulation Factor Concentrate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Coagulation Factor Concentrate market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Recombinant Coagulation Factor Concentrate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Recombinant Coagulation Factor Concentrate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Alprolix, Benefix, Idelvion, Lxinity, Rebinyn, Rixubis, CSL, Baxalta, Sanofi, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Recombinant Coagulation Factor Concentrate market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
250 IU
500 IU
1000 IU
2000 IU
Market segment by Application
Hopistial
Clinic
Others
Major players covered
Bayer
Alprolix
Benefix
Idelvion
Lxinity
Rebinyn
Rixubis
CSL
Baxalta
Sanofi
Biogen
Pfizer
Novo Disk
Baxter
Wyeth
Beijing Tiantan Biological Products
SHANGHAI RAAS
Taibang Biologic Group
HUALAN BIOLOGICAL ENGINEERING
Green Cross
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Coagulation Factor Concentrate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Recombinant Coagulation Factor Concentrate, with price, sales quantity, revenue, and global market share of Recombinant Coagulation Factor Concentrate from 2020 to 2025.
Chapter 3, the Recombinant Coagulation Factor Concentrate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Coagulation Factor Concentrate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Recombinant Coagulation Factor Concentrate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Coagulation Factor Concentrate.
Chapter 14 and 15, to describe Recombinant Coagulation Factor Concentrate sales channel, distributors, customers, research findings and conclusion.
Coagulation factor is the main drug for the treatment of hemophilia, and it has experienced the evolution and development from the first generation blood-derived coagulation factor products to the second generation recombinant products and the third generation long-acting recombinant products. Recombinant coagulation factors avoid the possibility of human infection and get rid of the dependence on plasma; long-acting products improve patient compliance and treatment convenience by prolonging the half-life of drugs, and long-acting recombinant coagulation factors are the trend of future research and development.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines. Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report is a detailed and comprehensive analysis for global Recombinant Coagulation Factor Concentrate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Recombinant Coagulation Factor Concentrate market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Coagulation Factor Concentrate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Coagulation Factor Concentrate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Coagulation Factor Concentrate market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Recombinant Coagulation Factor Concentrate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Recombinant Coagulation Factor Concentrate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Alprolix, Benefix, Idelvion, Lxinity, Rebinyn, Rixubis, CSL, Baxalta, Sanofi, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Recombinant Coagulation Factor Concentrate market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
250 IU
500 IU
1000 IU
2000 IU
Market segment by Application
Hopistial
Clinic
Others
Major players covered
Bayer
Alprolix
Benefix
Idelvion
Lxinity
Rebinyn
Rixubis
CSL
Baxalta
Sanofi
Biogen
Pfizer
Novo Disk
Baxter
Wyeth
Beijing Tiantan Biological Products
SHANGHAI RAAS
Taibang Biologic Group
HUALAN BIOLOGICAL ENGINEERING
Green Cross
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Coagulation Factor Concentrate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Recombinant Coagulation Factor Concentrate, with price, sales quantity, revenue, and global market share of Recombinant Coagulation Factor Concentrate from 2020 to 2025.
Chapter 3, the Recombinant Coagulation Factor Concentrate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Coagulation Factor Concentrate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Recombinant Coagulation Factor Concentrate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Coagulation Factor Concentrate.
Chapter 14 and 15, to describe Recombinant Coagulation Factor Concentrate sales channel, distributors, customers, research findings and conclusion.
Table of Contents
141 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Recombinant Coagulation Factor Concentrate by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
